CTLA4 and non-small cell lung carcinoma: Additionally, several trials evaluated nivolumab plus anti-CTLA4 antibodies with or without chemotherapy as first-line treatment for NSCLC, and suggested that nivolumab plus anti-CTLA4 antibodies may be a promising modality (33, 51–53).